Browse by category

According to Professor Ahmed Ahmed, President of the British Obesity and Metabolic Specialist Society, robotic metabolic and bariatric surgery (rMBS) in the UK is still in the early stage of adoption. He said that there are several reasons why the speciality has been slower to adopt this technology compared with other surgical specialities such as urology, thoracic or colorectal. Ahmed Ahmed “I believe one of the reasons is so far there is no clear benefit of rMBS over the mo

Amylyx Pharmaceuticals has announced positive topline results from LUCIDITY, a 78-participant, multi-centre, randomised, double-blind, placebo-controlled Phase 3 clinical trial evaluating the efficacy and safety of avexitide, an investigational, first-in-class glucagon-like peptide-1 (GLP-1) receptor antagonist, in participants with post-bariatric hypoglycemia (PBH) following Roux-en-Y gastric bypass (RYGB) surgery. LUCIDITY met the FDA-agreed-upon primary endpoint demonstrat

An international study led by King’s College London, UK, has found that proposed new obesity definitions give greater insight into the ill health of metabolic bariatric surgery (MBS) candidates, compared with Body Mass Index (BMI). The study, found that people considered for MBS had marked variation in disease burden – the number and severity of diseases – and operation-related risks, despite having similar BMI. However, by reviewing clinical data from thousands of bariatric

Preoperative Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) neither augment nor detract from metabolic and bariatric surgery (MBS), at least for the first 12 months postoperatively, according to the study by researchers from the School of Medicine, University of California, San Francisco. GLP-1 RAs use has risen dramatically with some patients treated with GLP-1 RAs1 later pursue MBS. However, the researchers noted that preoperative GLP-1 RA exposure influences post-op

Minister of Health (MoH) of Kuwait has issued new standards for regulating metabolic bariatric surgeries (MBS) and non-surgical interventional procedures in public and private healthcare facilities. The Ministry has established a comprehensive regulatory framework based on clear standards covering healthcare facilities, medical practitioners, patient selection and assessment, follow-up procedures, and monitoring of outcomes and complications. The standards take effect immedia

Researchers from the Netherlands and Yale School of Medicine - who evaluated sex differences in health status before and outcomes after metabolic and bariatric surgery (MBS) among men, premenopausal women, and postmenopausal women - have reported that men had more health conditions before MBS and lost less weight after surgery. Postmenopausal women showed a similar pattern but to a lesser extent. For the study, the researchers analysed data from the National Bariatric Surgery

In a new position paper, the American College of Physicians (ACP) has issued several recommendations on how policymakers can increase accessibility of obesity treatment for adults and address modifiable factors that contribute to obesity like diet and physical activity. The paper also includes further recommendations on reducing stigma associated with obesity, improving understanding of obesity among physicians and increasing access to healthy food. According to research from

A new approach to defining obesity could help physicians better determine which patients need more intensive treatment by focusing on the effects of excess adiposity on organs and tissues rather than relying primarily on whether a person meets a set of metabolic risk thresholds. Researchers from LSU's Pennington Biomedical Research Center examine the concept of "metabolically healthy obesity" and argue that a newer framework distinguishing preclinical obesity from clinical ob

Aqua Medical has announced the successful treatment of the first US patient in its FDA authorised Investigational Device Exemption (IDE) clinical trial evaluating the company's proprietary Proximal Intestinal Mucosal Ablation (PIMA) procedure for the treatment of type 2 diabetes. Aqua Medical is investigating a new diabetes procedure called proximal intestinal mucosal ablation (Illustration courtesy of Aqua Medical) Aqua Medical's investigational PIMA procedure utilises the c

Medtronic has presented its next-generation compute platform for the operating room. Touch Surgery Aide - an AI-native surgical computing platform that powers the Touch Surgery ecosystem - enables real-time artificial intelligence during procedures. Touch Surgery Aide was presented at the Society of Robotic Surgery (SRS) 2026 Annual Meeting in Florida. Touch Surgery Aide and the Touch Surgery ecosystem Built on years of experience, the Touch Surgery ecosystem brings insights